Table 3.
Clinical characteristics of patients developing active tuberculosis infection after anti-TNF agent
| No. | IBD | Sex | Age of anti-TNFs (yr) | Anti-TNFs | Previous TB treatment | Screening IGRA | Screening TST | IS at screening | Prophylaxis | Interval to TB infection (wk) | IS at TB diagnosis | Extra-pulmonary TB | No. of involvement organ |
| 1 | CD | F | 21 | IFX | No | ND | ND | None | ND | 83 | CS + AZA | No | 1 |
| 2 | CD | M | 24 | ADA | No | + | ND | CS | INH | 22 | None | Yes | 1 |
| 3 | CD | M | 24 | IFX | No | - | ND | CS +AZA | ND | 35 | AZA | Yes | 3 |
| 4 | CD | M | 42 | IFX | Yes | - | ND | CS | ND | 46 | CS + AZA | Yes | 6 |
| 5 | CD | F | 34 | IFX | Yes | - | ND | AZA | ND | 23 | AZA | Yes | 1 |
| 6 | CD | M | 29 | IFX | No | - | ND | AZA | ND | 10 | AZA | Yes | 5 |
| 7 | CD | M | 41 | IFX | No | ND | - | AZA | ND | 12 | AZA | Yes | 1 |
| 81 | CD | M | 24 | IFX | No | ND | - | CS | ND | 8 | CS | Yes | 4 |
| 9 | CD | M | 27 | IFX | No | ND | - | AZA | ND | 22 | AZA | No | 1 |
| 10 | CD | M | 23 | IFX | Yes | + | - | AZA | ND | 8 | CS + AZA | Yes | 1 |
| 11 | CD | M | 21 | IFX | No | - | Unknown | CS +AZA | ND | 129 | CS + AZA | Yes | 3 |
| 12 | UC | M | 32 | IFX | No | + | ND | AZA | INH + RFP | 40 | AZA | Yes | 4 |
| 13 | UC | M | 70 | IFX | No | - | ND | AZA | ND | 142 | AZA | No | 1 |
| 14 | UC | M | 21 | IFX | No | - | ND | CS +AZA | ND | 52 | AZA | Yes | 3 |
| 15 | UC | M | 56 | IFX | No | - | ND | AZA | ND | 47 | AZA | Yes | 2 |
| 16 | UC | F | 25 | IFX | No | + | - | AZA | ND | 12 | AZA | Yes | 2 |
1
This patient died 55 d after miliary tuberculosis diagnosis due to devastating acute renal failure. IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; IFX: Infliximab; ADA: Adalimumab; ND: Not done; TB: Tuberculosis; IGRA: Interferon gamma release assay; TST: Tuberculin skin test; IS: Immunosuppressant; CS: Corticosteroid; AZA: Azathioprine; INH: Isoniazid; RFP: Rifampin.